WallStreetZenWallStreetZen

NASDAQ: SUPN
Supernus Pharmaceuticals Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsRevenueDividendOwnership

Be the first to know when Wall Street analysts revise their SUPN stock forecasts and price targets.

Forecast return on equity

Is SUPN forecast to generate an efficient return?

Company
37.85%
Industry
47.11%
Market
174.26%
SUPN's Return on Equity is... subscribe to Premium to read more.
Forecast High Return on Equity Forecast

Forecast return on assets

Is SUPN forecast to generate an efficient return on assets?

Company
27.16%
Industry
18.42%
SUPN is forecast to generate... subscribe to Premium to read more.
Forecast Return on Assets vs Industry Forecast

SUPN earnings per share forecast

What is SUPN's earnings per share in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$2.20
Avg 2 year Forecast
$4.00
Avg 3 year Forecast
$5.56

SUPN revenue forecast

What is SUPN's revenue in the next 3 years based on estimates from 8 analysts?

Avg 1 year Forecast
$884.6M+13.87%
Avg 2 year Forecast
$1.0B+33.88%
Avg 3 year Forecast
$1.2B+53.7%
SUPN's revenue is forecast to... subscribe to Premium to read more.
Forecast High Revenue Growth Forecast

SUPN revenue growth forecast

How is SUPN forecast to perform vs Drug Manufacturers - Specialty & Generic companies and vs the US market?

Company
15.41%
Industry
9.17%
Market
13.95%
SUPN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
SUPN's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

SUPN vs Pharmaceutical Stocks

TickerPricePrice TargetUp/downsideConsensus
SUPN$48.05N/AN/A
RGC$6.37N/AN/A
PBH$49.42$67.67+36.92%Buy
HCM$11.44$20.00+74.83%Strong Buy
ANIP$86.03$124.00+44.14%Strong Buy
View Top Pharmaceutical Stocks

Supernus Pharmaceuticals Stock Forecast FAQ

What is SUPN's earnings growth forecast for 2026-2028?

(NASDAQ: SUPN) Supernus Pharmaceuticals's forecast annual earnings growth rate of N/A is not forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast earnings growth rate of 14.28%, and while it is not forecast to beat the US market's average forecast earnings growth rate of 34.17%.

Supernus Pharmaceuticals's earnings in 2026 is -$29,016,000.On average, 8 Wall Street analysts forecast SUPN's earnings for 2026 to be $127,675,778, with the lowest SUPN earnings forecast at $63,704,398, and the highest SUPN earnings forecast at $179,778,036. On average, 8 Wall Street analysts forecast SUPN's earnings for 2027 to be $232,066,020, with the lowest SUPN earnings forecast at $150,729,155, and the highest SUPN earnings forecast at $290,082,526.

In 2028, SUPN is forecast to generate $322,642,809 in earnings, with the lowest earnings forecast at $250,267,277 and the highest earnings forecast at $396,121,096.

If you're new to stock investing, here's how to buy Supernus Pharmaceuticals stock.

What is SUPN's revenue growth forecast for 2026-2028?

(NASDAQ: SUPN) Supernus Pharmaceuticals's forecast annual revenue growth rate of 15.41% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 9.17%, and it is also forecast to beat the US market's average forecast revenue growth rate of 13.95%.

Supernus Pharmaceuticals's revenue in 2026 is $776,833,000.On average, 8 Wall Street analysts forecast SUPN's revenue for 2026 to be $51,342,517,594, with the lowest SUPN revenue forecast at $48,858,997,932, and the highest SUPN revenue forecast at $53,171,929,600. On average, 8 Wall Street analysts forecast SUPN's revenue for 2027 to be $60,361,309,840, with the lowest SUPN revenue forecast at $56,671,144,379, and the highest SUPN revenue forecast at $63,553,494,495.

In 2028, SUPN is forecast to generate $69,299,426,874 in revenue, with the lowest revenue forecast at $63,379,375,332 and the highest revenue forecast at $73,942,604,554.

What is SUPN's forecast return on assets (ROA) for 2026-2029?

(NASDAQ: SUPN) forecast ROA is 27.16%, which is higher than the forecast US Drug Manufacturers - Specialty & Generic industry average of 18.42%.

What is SUPN's Earnings Per Share (EPS) forecast for 2026-2028?

(NASDAQ: SUPN) Supernus Pharmaceuticals's current Earnings Per Share (EPS) is -$0.51. On average, analysts forecast that SUPN's EPS will be $2.20 for 2026, with the lowest EPS forecast at $1.10, and the highest EPS forecast at $3.10. On average, analysts forecast that SUPN's EPS will be $4.00 for 2027, with the lowest EPS forecast at $2.60, and the highest EPS forecast at $5.00. In 2028, SUPN's EPS is forecast to hit $5.56 (min: $4.31, max: $6.83).

What is SUPN's forecast return on equity (ROE) for 2026-2029?

(NASDAQ: SUPN) forecast ROE is 37.85%, which is considered strong.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.